A new drug from Roche for women with an incurable form of breast cancer is too expensive for routine use on Britain's state-run health service even after a discount, the country's healthcare cost watchdog ruled on Friday. The National Institute for Health and Clinical Excellence (NICE) said it was "disappointed" Roche had decided against offering Kadcyla at a price that would make it affordable for routine use on the National Health Service (NHS). NICE, which is responsible for deciding if drugs should be used on the NHS, originally called for Roche to reduce the price of Kadcyla in April. This second rebuff forms part of a growing debate among healthcare authorities in Europe about the high price of modern medicines, especially those for treating cancer. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment